Molecular Partners AG (MOLN) is a Biotechnology company in the Healthcare sector, currently trading at $4.14. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Analyst consensus target is MOLN = $13 (+214% upside).
Valuation: MOLN trades at a trailing Price-to-Earnings (P/E) of -2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.07.
Net income is $62M (loss), growing at -51.3%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+26.8 pp trend).
Balance sheet: total debt is $4M against $80M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 8.79 (strong liquidity). Debt-to-assets is 3.6%. Total assets: $102M.
Analyst outlook: 1 / 4 analysts rate MOLN as buy (25%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 52/100 (Partial), Income ?/100 (Fail).
